Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation

R. Champlin, I. Khouri, P. Anderlini, J. Gajewski, S. Kornblau, J. Molldrem, A. Shimoni, N. Ueno, S. Giralt

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Allogeneic hematopoietic transplantation is an effective therapy for a range of malignancies. High doses of myelosuppressive chemotherapy or radiation have been used in preparative regimens with the goal of preventing graft rejection and eradicating malignancy. Much of the benefit of transplantation, however, results from graft-versus-malignancy effects, mediated by donor immunocompetent cells. An alternative approach is to utilize less toxic, nonmyeloablative preparative regimens to achieve engraftment and allow graft-versus-malignancy effects to develop. This strategy reduces the risk of treatment-related mortality and allows transplantation for elderly or medically infirm patients not eligible for myeloablative therapy. Nonmyeloablative preparative regimens appear promising in diagnoses sensitive to graft-versus-malignancy effects and provide a platform for further development of cellular immunotherapy. Controlled clinical trials are warranted to define the role of nonmyeloablative allogeneic transplants in a range of hematologic malignancies and selected solid tumors.

Original languageEnglish (US)
JournalBone Marrow Transplantation
Volume27
Issue numberSUPPL. 2
StatePublished - 2001
Externally publishedYes

Fingerprint

Homologous Transplantation
Transplants
Neoplasms
Transplantation
Poisons
Controlled Clinical Trials
Graft Rejection
Hematologic Neoplasms
Immunotherapy
Therapeutics
Tissue Donors
Radiation
Drug Therapy
Mortality

Keywords

  • Graft-versus-malignancy effect
  • Nonmyeloablative allogeneic transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Champlin, R., Khouri, I., Anderlini, P., Gajewski, J., Kornblau, S., Molldrem, J., ... Giralt, S. (2001). Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplantation, 27(SUPPL. 2).

Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. / Champlin, R.; Khouri, I.; Anderlini, P.; Gajewski, J.; Kornblau, S.; Molldrem, J.; Shimoni, A.; Ueno, N.; Giralt, S.

In: Bone Marrow Transplantation, Vol. 27, No. SUPPL. 2, 2001.

Research output: Contribution to journalArticle

Champlin, R, Khouri, I, Anderlini, P, Gajewski, J, Kornblau, S, Molldrem, J, Shimoni, A, Ueno, N & Giralt, S 2001, 'Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation', Bone Marrow Transplantation, vol. 27, no. SUPPL. 2.
Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplantation. 2001;27(SUPPL. 2).
Champlin, R. ; Khouri, I. ; Anderlini, P. ; Gajewski, J. ; Kornblau, S. ; Molldrem, J. ; Shimoni, A. ; Ueno, N. ; Giralt, S. / Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. In: Bone Marrow Transplantation. 2001 ; Vol. 27, No. SUPPL. 2.
@article{f78a310a1076449e8affa3df48f97124,
title = "Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation",
abstract = "Allogeneic hematopoietic transplantation is an effective therapy for a range of malignancies. High doses of myelosuppressive chemotherapy or radiation have been used in preparative regimens with the goal of preventing graft rejection and eradicating malignancy. Much of the benefit of transplantation, however, results from graft-versus-malignancy effects, mediated by donor immunocompetent cells. An alternative approach is to utilize less toxic, nonmyeloablative preparative regimens to achieve engraftment and allow graft-versus-malignancy effects to develop. This strategy reduces the risk of treatment-related mortality and allows transplantation for elderly or medically infirm patients not eligible for myeloablative therapy. Nonmyeloablative preparative regimens appear promising in diagnoses sensitive to graft-versus-malignancy effects and provide a platform for further development of cellular immunotherapy. Controlled clinical trials are warranted to define the role of nonmyeloablative allogeneic transplants in a range of hematologic malignancies and selected solid tumors.",
keywords = "Graft-versus-malignancy effect, Nonmyeloablative allogeneic transplantation",
author = "R. Champlin and I. Khouri and P. Anderlini and J. Gajewski and S. Kornblau and J. Molldrem and A. Shimoni and N. Ueno and S. Giralt",
year = "2001",
language = "English (US)",
volume = "27",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation

AU - Champlin, R.

AU - Khouri, I.

AU - Anderlini, P.

AU - Gajewski, J.

AU - Kornblau, S.

AU - Molldrem, J.

AU - Shimoni, A.

AU - Ueno, N.

AU - Giralt, S.

PY - 2001

Y1 - 2001

N2 - Allogeneic hematopoietic transplantation is an effective therapy for a range of malignancies. High doses of myelosuppressive chemotherapy or radiation have been used in preparative regimens with the goal of preventing graft rejection and eradicating malignancy. Much of the benefit of transplantation, however, results from graft-versus-malignancy effects, mediated by donor immunocompetent cells. An alternative approach is to utilize less toxic, nonmyeloablative preparative regimens to achieve engraftment and allow graft-versus-malignancy effects to develop. This strategy reduces the risk of treatment-related mortality and allows transplantation for elderly or medically infirm patients not eligible for myeloablative therapy. Nonmyeloablative preparative regimens appear promising in diagnoses sensitive to graft-versus-malignancy effects and provide a platform for further development of cellular immunotherapy. Controlled clinical trials are warranted to define the role of nonmyeloablative allogeneic transplants in a range of hematologic malignancies and selected solid tumors.

AB - Allogeneic hematopoietic transplantation is an effective therapy for a range of malignancies. High doses of myelosuppressive chemotherapy or radiation have been used in preparative regimens with the goal of preventing graft rejection and eradicating malignancy. Much of the benefit of transplantation, however, results from graft-versus-malignancy effects, mediated by donor immunocompetent cells. An alternative approach is to utilize less toxic, nonmyeloablative preparative regimens to achieve engraftment and allow graft-versus-malignancy effects to develop. This strategy reduces the risk of treatment-related mortality and allows transplantation for elderly or medically infirm patients not eligible for myeloablative therapy. Nonmyeloablative preparative regimens appear promising in diagnoses sensitive to graft-versus-malignancy effects and provide a platform for further development of cellular immunotherapy. Controlled clinical trials are warranted to define the role of nonmyeloablative allogeneic transplants in a range of hematologic malignancies and selected solid tumors.

KW - Graft-versus-malignancy effect

KW - Nonmyeloablative allogeneic transplantation

UR - http://www.scopus.com/inward/record.url?scp=0034992547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034992547&partnerID=8YFLogxK

M3 - Article

C2 - 11436116

AN - SCOPUS:0034992547

VL - 27

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - SUPPL. 2

ER -